Education
About Us
Working with TipRanks
Follow Us
Lyka Labs Limited (IN:LYKALABS)
:LYKALABS
LYKALABS Stock Chart & Stats
₹94.40
-₹1.55(-0.97%)
At close: 4:00 PM EST
₹94.40
-₹1.55(-0.97%)
Day’s Range― - ―
52-Week Range₹56.60 - ₹128.60
Previous CloseN/A
Volume78.41K
Average Volume (3M)3.02K
Market Cap
₹2.19B
Enterprise Value₹2.47B
Total Cash (Recent Filing)₹18.36M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding35,690,000
10 Day Avg. Volume1,252
30 Day Avg. Volume3,017
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)3.58
Price to Sales (P/S)2.64
P/FCF Ratio-26.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained revenue expansion near 75% indicates durable demand for Lyka Labs' formulations and successful market penetration. Over 2–6 months this supports scale economies, distribution leverage and funding for product development or geographic expansion, strengthening long-term growth potential.
Improving Operating MarginsImproved EBIT and EBITDA margins suggest the company is extracting more profit per rupee of sales through better cost control or higher-margin products. Margin expansion enhances cash generation potential and resilience to input-cost shocks, supporting sustainable operating leverage over time.
Strengthened Equity & Lower LeverageRising shareholder equity and a falling debt-to-equity ratio indicate improving capitalization and reduced financial risk. This bolsters balance sheet resilience, increases capacity to fund capex or acquisitions internally, and lowers vulnerability to interest-rate or covenant pressures in the medium term.
Bears Say
High Overall LiabilitiesPersistently high liabilities create ongoing solvency and liquidity pressure despite improved equity. Over months this raises refinancing, covenant and interest-service risks, limits flexibility for strategic investments, and can amplify impacts from demand or margin shocks on cash flows.
Negative Free Cash FlowNegative free cash flow driven by elevated capital spending means profits are not translating into discretionary cash. This constrains internal funding for growth or debt reduction, increases reliance on external financing, and can pressure liquidity and strategic options over the coming quarters.
Large EPS ContractionA steep decline in EPS growth signals volatile or deteriorating earnings quality despite revenue gains. Over the medium term this raises questions about sustainable net profitability, potential one-off impacts or margin pressures, and the company's capacity to finance expansions from earnings.
Lyka Labs Limited News
LYKALABS FAQ
What was Lyka Labs Limited’s price range in the past 12 months?
Lyka Labs Limited lowest stock price was ₹56.60 and its highest was ₹128.60 in the past 12 months.
What is Lyka Labs Limited’s market cap?
Lyka Labs Limited’s market cap is ₹2.19B.
When is Lyka Labs Limited’s upcoming earnings report date?
Lyka Labs Limited’s upcoming earnings report date is Jun 02, 2026 which is in 89 days.
How were Lyka Labs Limited’s earnings last quarter?
Lyka Labs Limited released its earnings results on Jan 29, 2026. The company reported ₹0 earnings per share for the quarter, the consensus estimate of N/A by ₹0.
Is Lyka Labs Limited overvalued?
According to Wall Street analysts Lyka Labs Limited’s price is currently Overvalued.
Does Lyka Labs Limited pay dividends?
Lyka Labs Limited does not currently pay dividends.
What is Lyka Labs Limited’s EPS estimate?
Lyka Labs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lyka Labs Limited have?
Lyka Labs Limited has 35,690,000 shares outstanding.
What happened to Lyka Labs Limited’s price movement after its last earnings report?
Lyka Labs Limited reported an EPS of ₹0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -3.741%.
Which hedge fund is a major shareholder of Lyka Labs Limited?
Currently, no hedge funds are holding shares in IN:LYKALABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lyka Labs Limited
Lyka Labs Limited, a pharmaceutical company, engages in development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, muscle relaxant, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. In addition, it provides products and services in therapeutic categories, such as intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetologist, urology, wound care, and anesthesia, as well as deals in pharmaceutical products. The company offers its products in various formulations, including injections, creams, ointments, gels, and lotions. It also exports its products to Bangladesh, Combodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam. Lyka Labs Limited was incorporated in 1976 and is based in Mumbai, India.
Technical Analysis
Brooks Laboratories Limited
―
Medico Remedies Ltd.
―
Nureca Ltd.
―
―
Zim Laboratories Ltd.
―